Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Prior treatment

• Clinically significant cardiac disease including stable angina, acute myocardial infraction 6 months prior to screening
• Ongoing clinically significant toxicity associated with prior treatment (including radiotherapy or surgery).
• Part D, F, and G Only: Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.

Other illness

• Active bleeding conditions
• Ocular surface disease at the time of enrollment (Note: cataract is not considered active ocular surface disease for this protocol)
• Other cancer: known past or current malignancy other than inclusion diagnosis.
• Inflammatory lung disease. Participants with pulmonary disease are allowed if systemic steroids and long-term oxygen are not required

Other

• Participants with primary neuroendocrine or sarcomatoid histologies. For HNSCC, participants may not have a primary site of nasopharynx or salivary gland.
• Uncontrolled tumor-related pain
• Peripheral neuropathy greater than or equal to Grade 2
• Active brain metastasis

• Parts A, B, and C
  • Relapsed, locally-advanced or metastatic colorectal or pancreatic cancer, sqNSCLC, or HNSCC participants who are not candidates for standard therapy.
  • All participants must have experienced disease progression on or after their most recent systemic therapy.
  • Colorectal cancer (closed to enrollment): participants must have received prior therapy with each of following agents, if eligible: a fluoropyrimidine, oxaliplatin, irinotecan, and/or bevacizumab. Participants should have received no more than 3 systemic regimens in the metastatic setting.
  • sqNSCLC (closed to enrollment): Participants with NSCLC must have predominant squamous histology. Participants must have received prior therapy with a platinum-based treatment and a checkpoint inhibitor (CPI), if eligible. Participants should have received no more than 3 lines of systemic therapy in the metastatic setting.
  • Participants eligible for a tyrosine kinase inhibitor should have received such therapy. These participants should have received no more than 4 lines of systemic therapy in the metastatic setting.
  • Exocrine pancreatic adenocarcinoma (closed to enrollment): Participants with exocrine pancreatic adenocarcinoma must have predominant adenocarcinoma histology. Participants must have received prior therapy with a gemcitabine-based or 5FU-based regimen, if eligible, and should have received no more than 1 systemic regimen in the unresectable or metastatic setting.
  • HNSCC (closed to enrollment): Participants with HNSCC in Part C must have received prior therapy with a platinum-based regimen and/or a checkpoint inhibitor (CPI), if eligible, and must have experienced disease progression following such therapy. Participants should have received no more than 3 systemic lines of therapy in the recurrent or metastatic setting.
• Part E
  • Part E is closed to enrollment.
  • Participants with HNSCC must have experienced disease progression on or after their most recent systemic therapy. Participants should have received no more than 1 or 2 systemic lines of therapy in the recurrent/metastatic setting as specified below. Participants must have received a platinum-based regimen and a PD-(L)1 inhibitor.
• Parts D, F, and G
  • Part D and F are closed to enrollment. Part G will enroll only participants with HNSCC.
  • Participants with HNSCC must have received no previous systemic therapy in the recurrent or metastatic disease setting.
  • Part D only
  • Participants with NSCLC must have histologically or cytologically documented squamous cell NSCLC and must have received no previous systemic therapy for metastatic disease or radiation therapy to the lung that is \> 30 Gy within 6 months of the first dose of study treatment.
  • PD-L1 biomarker expression as determined by a PD-L1 IHC assay should be available
  • Part F only
  • Participants must have CPS ≥1 by local PD-L1 IHC assay to be eligible for enrollment. Participants must be able to submit a tissue sample for retrospective PD-L1 testing. Tissue may be fresh biopsy or archival, collected within 2 years of Cycle 1 Day 1.
  • Part G only
  • Part G cohort was not opened.
  • Non-EU eligibility criteria: No CPS requirement for the cohort evaluating tisotumab vedotin in combination with pembrolizumab and carboplatin.
  • EU-specific eligibility criteria: Participants must have a CPS ≥1 by local PD-L1 IHC assay.
  • Participants must be able to submit a tissue sample for retrospective PD-L1 testing. Tissue may be fresh biopsy or archival, collected within 2 years of Cycle 1 Day 1.
• Baseline measurable disease as measured by RECIST v1. 1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.